[
  {
    "ts": null,
    "headline": "Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy.",
    "summary": "Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.",
    "url": "https://finnhub.io/api/news?id=4d8e60c1eb78c5729d648793d48c007fd43908f786e91158b26926e186ba1934",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745529840,
      "headline": "Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy.",
      "id": 134067781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.",
      "url": "https://finnhub.io/api/news?id=4d8e60c1eb78c5729d648793d48c007fd43908f786e91158b26926e186ba1934"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat",
    "summary": "Bristol Myers Squibb stock reversed higher Thursday after the drugmaker beat first-quarter expectations and raised its outlook for the year.",
    "url": "https://finnhub.io/api/news?id=537bd69db9f756a0659907bd9c60066f6791faea0aeaaccc10e0905dbc1b1350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745525531,
      "headline": "Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat",
      "id": 134067782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock reversed higher Thursday after the drugmaker beat first-quarter expectations and raised its outlook for the year.",
      "url": "https://finnhub.io/api/news?id=537bd69db9f756a0659907bd9c60066f6791faea0aeaaccc10e0905dbc1b1350"
    }
  },
  {
    "ts": null,
    "headline": "Dividends Could Be Under Threat. Here Are 9 Stocks With Safe 5% Yields.",
    "summary": "Goldman Sachs expects companies’ spending on dividends to increase less quickly in 2025 than it had forecast earlier.",
    "url": "https://finnhub.io/api/news?id=b69850e34d1ec9805a127a5fa48932da2a43d5b93ba9ee09ad8cfdc256e791d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745524200,
      "headline": "Dividends Could Be Under Threat. Here Are 9 Stocks With Safe 5% Yields.",
      "id": 134067783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Goldman Sachs expects companies’ spending on dividends to increase less quickly in 2025 than it had forecast earlier.",
      "url": "https://finnhub.io/api/news?id=b69850e34d1ec9805a127a5fa48932da2a43d5b93ba9ee09ad8cfdc256e791d6"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) demonstrated a strong performance by shifting from a net loss to profit in Q1 2025, and increased its revenue guidance, reflecting confidence in its growth and legacy portfolios. However, despite these positive earnings and guidance revisions, Bristol-Myers saw a price movement of 2% downward over the past week, contrasting with a vibrant market that rose sharply by 2.3% due to favorable earnings reports across sectors and anticipation of tariff changes. The...",
    "url": "https://finnhub.io/api/news?id=a56edd3aa39fd47771f31eff482d34a5186a2e5c24ae6d72ef23ca5fdb18cc7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745516262,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance",
      "id": 134067784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) demonstrated a strong performance by shifting from a net loss to profit in Q1 2025, and increased its revenue guidance, reflecting confidence in its growth and legacy portfolios. However, despite these positive earnings and guidance revisions, Bristol-Myers saw a price movement of 2% downward over the past week, contrasting with a vibrant market that rose sharply by 2.3% due to favorable earnings reports across sectors and anticipation of tariff changes. The...",
      "url": "https://finnhub.io/api/news?id=a56edd3aa39fd47771f31eff482d34a5186a2e5c24ae6d72ef23ca5fdb18cc7d"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up After Merck Earnings -- Health Care Roundup",
    "summary": "Health Care Up After Merck Earnings -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=c88ade609d2a6d1db48e833b7c6f445700ce00d76949b7894632a9e030fab915",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745513100,
      "headline": "Health Care Up After Merck Earnings -- Health Care Roundup",
      "id": 134074860,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Health Care Up After Merck Earnings -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=c88ade609d2a6d1db48e833b7c6f445700ce00d76949b7894632a9e030fab915"
    }
  },
  {
    "ts": null,
    "headline": "Netflix's new high, Bristol Myers outlook, Texas Instruments pops",
    "summary": "As part of today's Market Minute, Brad Smith outlines some of the top stories of the trading session. Netflix (NFLX) stock hits a fresh all-time high, with some Wall Street analysts saying the stock is a recession-resistant play. Bristol Myers Squibb (BMY) lifts its outlook on strong sales driven by its cancer drug. Texas Instruments (TXN) stock pops after the company's earnings beat estimates amid what the CEO calls a \"real recovery' for its industrials business. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=05a2f971cc82b0b03dbc11f643ba849a26adc0aa7c6005eac0ed79e7fb62a38a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745511070,
      "headline": "Netflix's new high, Bristol Myers outlook, Texas Instruments pops",
      "id": 134067394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "As part of today's Market Minute, Brad Smith outlines some of the top stories of the trading session. Netflix (NFLX) stock hits a fresh all-time high, with some Wall Street analysts saying the stock is a recession-resistant play. Bristol Myers Squibb (BMY) lifts its outlook on strong sales driven by its cancer drug. Texas Instruments (TXN) stock pops after the company's earnings beat estimates amid what the CEO calls a \"real recovery' for its industrials business. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=05a2f971cc82b0b03dbc11f643ba849a26adc0aa7c6005eac0ed79e7fb62a38a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact",
    "summary": "Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. Sales decreased 6% year-over-year, or 4% when adjusted for foreign exchange impacts. U.S. revenues of $7.9 billion decreased by 7%, and International revenues of $3.3 billion decreased by 2% or increased by 2% Ex-FX. Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis (18% Ex-FX), primarily driven by Opdivo, Breyanzi, Reblozyl, and Camzyos a",
    "url": "https://finnhub.io/api/news?id=09a4195d706ffa2c69b009419544da8b19ac434f0adad13d2dedc3e0b7d9844e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745510117,
      "headline": "Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact",
      "id": 134067786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. Sales decreased 6% year-over-year, or 4% when adjusted for foreign exchange impacts. U.S. revenues of $7.9 billion decreased by 7%, and International revenues of $3.3 billion decreased by 2% or increased by 2% Ex-FX. Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis (18% Ex-FX), primarily driven by Opdivo, Breyanzi, Reblozyl, and Camzyos a",
      "url": "https://finnhub.io/api/news?id=09a4195d706ffa2c69b009419544da8b19ac434f0adad13d2dedc3e0b7d9844e"
    }
  },
  {
    "ts": null,
    "headline": "BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook",
    "summary": "BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.",
    "url": "https://finnhub.io/api/news?id=a8f2fdb40b901a34e7bad48cf6820202fd709e175e1c259b2bfa7371538dd280",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745510040,
      "headline": "BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook",
      "id": 134067787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.",
      "url": "https://finnhub.io/api/news?id=a8f2fdb40b901a34e7bad48cf6820202fd709e175e1c259b2bfa7371538dd280"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics",
    "summary": "The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=ee1f1f77fb745ea800a88d41a86671e30aec7992a66cb5ecb550fadb244f1c19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745501431,
      "headline": "Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics",
      "id": 134067788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=ee1f1f77fb745ea800a88d41a86671e30aec7992a66cb5ecb550fadb244f1c19"
    }
  },
  {
    "ts": null,
    "headline": "Drugmakers brace for Trump tariffs with production shifts",
    "summary": "Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs, although he has since indicated that levies are coming, arguing that the U.S. needs more drug manufacturing so it does not have to rely on other countries for its supply of medicines.  So far, there is little clarity on the rates and timings related to tariffs, but the industry is expecting a big hit if Trump goes ahead with his plans, since the United States is the largest market for drugs in the world, with more than $200 billion in imports.  Last week, the Trump administration announced probes into pharmaceutical imports, setting the stage for levies on the sector and prompting several major drugmakers to consider moving production to sites where the drugs are sold.",
    "url": "https://finnhub.io/api/news?id=1c03bb136d9decfcf1f49b4d7bbec3f4f0103cbb63dc3efcfad0cd73a2b58475",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745498573,
      "headline": "Drugmakers brace for Trump tariffs with production shifts",
      "id": 134059604,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs, although he has since indicated that levies are coming, arguing that the U.S. needs more drug manufacturing so it does not have to rely on other countries for its supply of medicines.  So far, there is little clarity on the rates and timings related to tariffs, but the industry is expecting a big hit if Trump goes ahead with his plans, since the United States is the largest market for drugs in the world, with more than $200 billion in imports.  Last week, the Trump administration announced probes into pharmaceutical imports, setting the stage for levies on the sector and prompting several major drugmakers to consider moving production to sites where the drugs are sold.",
      "url": "https://finnhub.io/api/news?id=1c03bb136d9decfcf1f49b4d7bbec3f4f0103cbb63dc3efcfad0cd73a2b58475"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers says schizophrenia drug launch ‘off to a solid start’",
    "summary": "Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily beating Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=0e28a1da6573da80969a46c6ac7f7c8d931b0e5149d3efd4c1eb552a9029604c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745496720,
      "headline": "Bristol Myers says schizophrenia drug launch ‘off to a solid start’",
      "id": 134067789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily beating Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=0e28a1da6573da80969a46c6ac7f7c8d931b0e5149d3efd4c1eb552a9029604c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates",
    "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of 19.21% and 4.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=9e62f9ee81d32db3b1c7b7ab3fb11724b8ebbe1983e2a51dc7e971280174f2e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745496606,
      "headline": "Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates",
      "id": 134067790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of 19.21% and 4.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=9e62f9ee81d32db3b1c7b7ab3fb11724b8ebbe1983e2a51dc7e971280174f2e6"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ETCompany ParticipantsChuck Triano - SVP and Head of IRChris...",
    "url": "https://finnhub.io/api/news?id=9d8d131bbf98d8c38a382ed83278bb00169cbe7acf49233004d8ace91247f04d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745496108,
      "headline": "Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript",
      "id": 134062739,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ETCompany ParticipantsChuck Triano - SVP and Head of IRChris...",
      "url": "https://finnhub.io/api/news?id=9d8d131bbf98d8c38a382ed83278bb00169cbe7acf49233004d8ace91247f04d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Is A Good Pick",
    "summary": "Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here to find out why BMY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=2dae8c9c12ddaac8cb22f5b437cc093af4edd07a1aece41978f1c84e2ed627eb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745495804,
      "headline": "Bristol-Myers Squibb Is A Good Pick",
      "id": 134062682,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617236488/image_1617236488.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here to find out why BMY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=2dae8c9c12ddaac8cb22f5b437cc093af4edd07a1aece41978f1c84e2ed627eb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 5.6% year on year to $11.2 billion. The company’s full-year revenue guidance of $46.3 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.80 per share was 19.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=d4f14555fb27e669fe56870f143fa7d8dde63cbc03fc7959fdaf156835762f28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745495277,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations",
      "id": 134059605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 5.6% year on year to $11.2 billion. The company’s full-year revenue guidance of $46.3 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.80 per share was 19.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=d4f14555fb27e669fe56870f143fa7d8dde63cbc03fc7959fdaf156835762f28"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade",
    "summary": "Bristol-Myers Squibb Company's Q1 2025 earnings reveal revenue decline but EPS growth. Click to discover BMY challenges, dividend appeal, and pipeline potential.",
    "url": "https://finnhub.io/api/news?id=21d3ed5e4f47878cfe3869b6f7216e5f461492a646607544ecbbf8eb8e9b4dc3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745493749,
      "headline": "Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade",
      "id": 134062308,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company's Q1 2025 earnings reveal revenue decline but EPS growth. Click to discover BMY challenges, dividend appeal, and pipeline potential.",
      "url": "https://finnhub.io/api/news?id=21d3ed5e4f47878cfe3869b6f7216e5f461492a646607544ecbbf8eb8e9b4dc3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales",
    "summary": "Bristol Myers Squibb reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to...",
    "url": "https://finnhub.io/api/news?id=4386522e9dade4aee21bdbb55c55ba04020cdce983654e09cbd9ec08dfa84799",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745493411,
      "headline": "Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales",
      "id": 134061994,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to...",
      "url": "https://finnhub.io/api/news?id=4386522e9dade4aee21bdbb55c55ba04020cdce983654e09cbd9ec08dfa84799"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance",
    "summary": "Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.",
    "url": "https://finnhub.io/api/news?id=4d87725b73551df31ee73ed86f47a4266ada9604e336dd3ce68e0af75fb85f91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745493180,
      "headline": "Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance",
      "id": 134059606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.",
      "url": "https://finnhub.io/api/news?id=4d87725b73551df31ee73ed86f47a4266ada9604e336dd3ce68e0af75fb85f91"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: Q1 Earnings Snapshot",
    "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year earlier. The Princeton, New Jersey-based company said it had profit of $1.20 per share. Earnings, adjusted for amortization costs and non-recurring costs, came to $1.80 per share.",
    "url": "https://finnhub.io/api/news?id=b6e4a581526ffef06e32f24440a52c8b1ea6f777cd99e112e0ca9af313e90d05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745493123,
      "headline": "Bristol Myers: Q1 Earnings Snapshot",
      "id": 134059607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year earlier. The Princeton, New Jersey-based company said it had profit of $1.20 per share. Earnings, adjusted for amortization costs and non-recurring costs, came to $1.80 per share.",
      "url": "https://finnhub.io/api/news?id=b6e4a581526ffef06e32f24440a52c8b1ea6f777cd99e112e0ca9af313e90d05"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales",
    "summary": "(Reuters) -Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.  The company's shares have dropped more than 20% over the past month as investor concerns about U.S. President Donald Trump's tariff threats have roiled the markets.  Chief Financial Officer David Elkins said in an interview that the company's global manufacturing footprint puts it in a good position to deal with whatever tariffs may come.",
    "url": "https://finnhub.io/api/news?id=36b0d85c728be249772d0a4f8997567b0a64371d9ba0e22b130fef9ce7d337c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745492585,
      "headline": "Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales",
      "id": 134059608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "(Reuters) -Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.  The company's shares have dropped more than 20% over the past month as investor concerns about U.S. President Donald Trump's tariff threats have roiled the markets.  Chief Financial Officer David Elkins said in an interview that the company's global manufacturing footprint puts it in a good position to deal with whatever tariffs may come.",
      "url": "https://finnhub.io/api/news?id=36b0d85c728be249772d0a4f8997567b0a64371d9ba0e22b130fef9ce7d337c9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Reports First Quarter Financial Results for 2025",
    "summary": "PRINCETON, N.J., April 24, 2025--Bristol Myers Squibb Reports First Quarter Financial Results for 2025",
    "url": "https://finnhub.io/api/news?id=154d88bf148be2e13ce2b9303130af458a7176b3c1b392068c3f1d0ec0d4b71c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745492340,
      "headline": "Bristol Myers Squibb Reports First Quarter Financial Results for 2025",
      "id": 134059609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., April 24, 2025--Bristol Myers Squibb Reports First Quarter Financial Results for 2025",
      "url": "https://finnhub.io/api/news?id=154d88bf148be2e13ce2b9303130af458a7176b3c1b392068c3f1d0ec0d4b71c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company 2025 Q1 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q1 earnings call.",
    "url": "https://finnhub.io/api/news?id=993b61bcdea25f01b193acd5efab90ae62c010c13525c4000d1868d91ec14238",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745487985,
      "headline": "Bristol-Myers Squibb Company 2025 Q1 - Results - Earnings Call Presentation",
      "id": 134061048,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q1 earnings call.",
      "url": "https://finnhub.io/api/news?id=993b61bcdea25f01b193acd5efab90ae62c010c13525c4000d1868d91ec14238"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance",
    "summary": "By Adriano Marchese Bristol Myers Squibb upgraded its guidance for the year after logging a swing to profit in the first quarter and better-than-expected revenue thanks to its growth portfolio....",
    "url": "https://finnhub.io/api/news?id=b1e9bf4758c945eca7ed64b10bd657a9a34de2d8be947f7c655c06546dfb3ef9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745479991,
      "headline": "Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance",
      "id": 134058504,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Adriano Marchese Bristol Myers Squibb upgraded its guidance for the year after logging a swing to profit in the first quarter and better-than-expected revenue thanks to its growth portfolio....",
      "url": "https://finnhub.io/api/news?id=b1e9bf4758c945eca7ed64b10bd657a9a34de2d8be947f7c655c06546dfb3ef9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance",
    "summary": "Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance",
    "url": "https://finnhub.io/api/news?id=9a56ee4287ef43aa06b6fe8130a32387bb781599ef780b482a27a00045b06cd2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745479020,
      "headline": "Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance",
      "id": 134074862,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance",
      "url": "https://finnhub.io/api/news?id=9a56ee4287ef43aa06b6fe8130a32387bb781599ef780b482a27a00045b06cd2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb : Q1 2025 Results Presentation",
    "summary": "Q1 2025 Results April 24, 2025 Not for Product Promotional Use Q1 2025...",
    "url": "https://finnhub.io/api/news?id=174bedabd078ce6ec6bd5c3cff685911db823aa6b6bb6c6ad1c3d491c421f07f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745478267,
      "headline": "Bristol Myers Squibb : Q1 2025 Results Presentation",
      "id": 134058299,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Q1 2025 Results April 24, 2025 Not for Product Promotional Use Q1 2025...",
      "url": "https://finnhub.io/api/news?id=174bedabd078ce6ec6bd5c3cff685911db823aa6b6bb6c6ad1c3d491c421f07f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb : Q1 2025 Results Presentation with Appendix",
    "summary": "Q1 2025 Results April 24, 2025 Not for Product Promotional Use Q1 2025...",
    "url": "https://finnhub.io/api/news?id=fe0ab03daf6754b8271e1d13d41c494be8747982735a17e960ddc5d67180bd1e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745478266,
      "headline": "Bristol Myers Squibb : Q1 2025 Results Presentation with Appendix",
      "id": 134058300,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Q1 2025 Results April 24, 2025 Not for Product Promotional Use Q1 2025...",
      "url": "https://finnhub.io/api/news?id=fe0ab03daf6754b8271e1d13d41c494be8747982735a17e960ddc5d67180bd1e"
    }
  }
]